- The global and local co-promotion will enable both companies to broaden access to innovative digital solutions and contribute to an easier and more seamless integration of diabetes management in daily routines
- Registered users of the mySugr app now have the ability to automatically upload blood glucose data from the Accu-Chek Connect meter. Additionally, users of the Accu-Chek Connect meter are granted free access to the pro-version of the mySugr Logbook app
- The agreement will come into effect initially in Germany and Austria, with the U.S. to follow shortly
BASEL, Switzerland, April 18, 2016 /PRNewswire/ --Roche Diabetes Care today announced the co-operation with mySugr, a diabetes service company providing apps to help people with diabetes to reduce the burden of managing their chronic condition. The agreement with mySugr will support both companies in broadening access to innovative digital solutions and contribute to an easier and more seamless integration of diabetes management in daily routines. The co-promotion agreement will initially start in Germany and Austria; with the U.S. and other markets to follow. Roche and mySugr will jointly market the product through their respective marketing and communication channels.
Digital health can motivate people to better manage their diabetes
The integration of Roche's Accu-Chek Connect meter with the mySugr app allows users to benefit from the collaboration in various ways, such as the ability to automatically upload blood glucose data into the app. Elements of fun, gamification and immediate feedback like the "diabetes monster" in the mySugr Logbook app playfully integrate diabetes management into daily routines. These unique features have helped mySugr establish the largest user base of any diabetes management app worldwide.
"This co-operation will bring true innovation to our customers," says Marcel Gmuender, Global Head of Roche Diabetes Care. "Digital diabetes care solutions have proven to help manage diabetes-related data more comprehensively. This makes data more meaningful1 and can ultimately lead to better therapy outcomes."
About mySugr
Founded in 2012 by people with diabetes for people with diabetes, mySugr creates mobile health solutions to minimize the daily struggles and challenges in diabetes management. True to their motto, "we make diabetes suck less," mySugr becomes a loyal companion by providing comprehensive care through app-based services during the often lonely and confusing times between doctor visits.
Their products are characterized by the intelligent combination of design, technology, and diabetes expertise to help people better manage their blood sugar and live happier, healthier lives. Particularly well-known is mySugr Logbook which has more than 600,000 registered users worldwide and focuses on automated tracking through connected devices, insulin dose calculations (approved for use in Europe), estimated HbA1c statistics, and clear reporting for effective therapy management with clinicians.
For more information, please visit mysugr.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normal and active as possible as well as to empowering healthcare professionals to manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs - contributing to an improved medical outcome. For more information please visit www.accu-chek.com.
All trademarks used or mentioned in this release are protected by law.
Roche Diabetes Care
Global Communications
Ute Volkmann
Phone: +49 621 759 9561
ute.volkmann@roche.com
www.roche.com / www.accu-chek.com
________________________________________________________________
References
1.Hinnen D, Buskirk A, Lyden M, Amstutz L, Hunter T, Parkin CG, Wagner R. Use of diabetes data management software reports by health care providers, patients with diabetes, and caregivers improves accuracy and efficiency of data analysis and interpretation compared with traditional logbook data: first results from the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES). J Diabetes Sci Technol. Pub online 2 Nov 2014. DOI: 10.1177/1932296814557188.
